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Abstract
B cells play an important role in the pathogenesis of both systemic and organ-specific autoimmune diseases. Autoreactive B
cells not only produce autoantibodies, but also are capable to efficiently present specific autoantigens to T cells.
Furthermore, B cells can secrete proinflammatory cytokines and amplify the vicious process of self-destruction. B cell-
directed therapy is a potentially important approach for treatment of various autoimmune diseases. The depletion of B cells
by anti-CD20/19 monoclonal antibody RetuximabH used in autoimmune diseases therapy leads to systemic side effects and
should be significantly improved. In this study we designed a repertoire of genetically engineered B cell killers that
specifically affected one kind of cells carrying a respective B cell receptor. We constructed immunotoxins (ITs), fused with c-
myc epitope as a model targeting sequence, based on barnase, Pseudomonas toxin, Shiga-like toxin E.coli and Fc domain of
human antibody IgGc1. C-MYC hybridoma cell line producing anti-c-myc IgG was chosen as a model for targeted cell
depletion. C-myc sequence fused with toxins provided addressed delivery of the toxic agent to the target cells. We
demonstrated functional activity of designed ITs in vitro and showed recognition of the fusion molecules by antibodies
produced by targeted hybridoma. To study specificity of the proposed B cells killing molecules, we tested a set of created
ITs ex vivo, using C-MYC and irrelevant hybridoma cell lines. Pseudomonas-containing IT showed one of the highest
cytotoxic effects on the model cells, however, possessed promiscuous specificity. Shiga-like toxin construct demonstrated
mild both cytotoxicity and specificity. Barnase and Fc-containing ITs revealed excellent balance between their legibility and
toxic properties. Moreover, barnase and Fc molecules fused with c-myc epitope were able to selectively deplete c-myc-
specific B cells and decrease production of anti-c-myc antibodies in culture of native splenocytes, suggesting their highest
therapeutic potential as targeted B cell killing agents.
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Introduction
Findings of the last two decades suggest that B cells play a
significant role in autoimmune diseases [1,2]. It may include several
pathways, such as production of antibodies (Abs) towards self-
antigens, immune complex formation [3], or cytokine and
chemokine secretion by autoreactive B cells [4,5,6]. It was shown
that Abs may be used as markers of the development [7,8] and
progression of autoimmune diseases [9]. Autoreactive B cells may
act as antigen-presenting cells in autoimmune diabetes and multiple
sclerosis [10], additionally being one of the major cytokine
producers in autoimmune disorders [11]. B cells producing Abs to
self-antigens act as pathogenic entities, but recent findings indicate
that distinct B cell subsets may also have regulatory functions by
suppressing unwanted autoaggressive T cells response, and thus,
ameliorate the progression of autoimmune diseases [12,13,14].
Thus, similar to the T cells [15], B cells may be considered as an
important target for the immune intervention.
Basically three B cell-directed strategies exist for treatment of
autoimmune disorders: (i) the administration of depleting Abs
targeting B cell-specific surface molecules; (ii) targeting B cell
receptor (BCR) signaling, which leads to apoptosis of B cells;
(iii) inactivation of B cells survival and activation factors. The first
approach was developed by several research groups [5,16,17],
using Abs raised against the B cell surface molecules CD19, CD20,
CD21, CD22 and CD23. These Abs have been successfully used
for in vivo B-cell-directed therapy. However, it should be
emphasized that only a limited number of them have been
approved for the clinical trials: RituximabH (human/murine
chimeric anti-human CD20(hCD20) monoclonal antibody) [4],
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OcrelizumabH (humanized anti-CD20 monoclonal antibody) [19].
The second strategy is focused on Abs specific to BCR-associated
transmembrane signaling proteins CD79a and CD79b, almost
exclusively exposed on the B cell surface [20]. Inhibition of B-cell
survival and proliferation by the blockade of CD40-CD40L
interaction [21,22] may be considered as an example of third
approach. Two members of TNF family BAFF (B-cell activating
factor) and APRIL (a proliferation including ligand) can also be
used as a target for antibody-mediated interruption of BAFF/
APRIL signaling pathway [23,24]. Administration of Belimu-
mabH, a humanized monoclonal antibody against soluble BAFF,
has been shown to be beneficial in clinical trials with patients with
moderate to severe rheumatoid arthritis [25]. Moreover, some
authors reported about administration of intravenous immuno-
globulins (IVIG) in therapy of murine experimental rheumatoid
arthritis model, and comparison of therapy by IVIG and sialylated
IgG Fc molecules (derived from either intravenous immune
globulin or human recombinant IgG1). However, mechanism of
action of recombinant sialylated IgG Fc is still not known [26].
Nevertheless, obtained drugs have massive side effects and
generally are non-specific. A number of patients with systemic
lupus erythematosus died in the context of being treated with
RituximabH according to the FDA official alert (www.fda.gov/
Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatient-
sandProviders/ucm126519.htm). Moreover, CD20 antibody-
mediated B-cell depletion before EAE induction substantially
exacerbated disease symptoms and increased infiltration of
encephalitogenic T cells into the CNS. Increased symptom
severity resulted from the depletion of a rare IL-10-producing
CD1d
hiCD5
+ regulatory B-cells subset (B10 cells), since the
adoptive transfer of splenic B10 cells before EAE induction
normalized EAE in B-cells-depleted mice [12]. RituximabH
treatment has been reported to cause the following serious adverse
events such as cardiac arrest, tumor lysis syndrome causing acute
renal failure, hepatitis B reactivation and other viral infections,
progressive multifocal leukoencephalopathy (PML), immune
toxicity with depletion of B cells from 70% to 80% in lymphoma
patients, or pulmonary toxicity [27,28].
Thus, the best immunotherapy should inhibit the pathogenic
function without influence on the regulatory abilities of B-cells.
The selective elimination of autoreactive B-cells by targeted
molecules seems to be the optimal way to realize this approach.
We have designed a panel of immunotoxins based either on (i)
barnase – ribonuclease from Bacillus amyloliquefaciens [29], (ii)
catalytic domain of Pseudomonas toxin, (iii) catalytic domain of
Shiga-like toxin E.coli, and (iv) Fc fragment of IgGc1 antibody.
The legibility and toxic properties of the different constructs were
thus investigated which of them could represent the best strategy
for specific B cells depletion.
Methods
Cells
Chinese hamster ovary cells (CHO), C-MYC and 1B4F4
hybridoma cells were cultured in DMEM (GIBCO Invitrogen,
USA) with 10% FBS (GIBCO Invitrogen, USA) supplemented
with 1x Antibiotic-Antimycotic solution (GIBCO Invitrogen,
USA), glutamine (GIBCO Invitrogen, USA), and non-essential
amino acids (Gibco Invitrogen, USA).
Construction of vectors and expression of proteins
The human IgGc1 Fc domain expression vector (pBudCE4.1/
CMV/Lead H/gamma) was obtained previously in our laboratory
[30]. The DNA encoding c-myc peptide (EQKLISEEDL) was
generated by PCR, sequenced and inserted into the pBudCE4.1/
CMV/Lead H/gamma plasmid. Stable CHO cells (CHO-K1
cells, ATCC CCL61) were transfected with pBudCE4.1/CMV/
Lead H/c-myc/linker/gamma plasmid by Lipofectanine
TM re-
agent (Invitrogen, USA) and cultured in the presence of Zeocin
(0.7 mg/ml) (Invitrogen, USA) in DMEM. Soluble Fc-c-myc
protein was purified from culture supernatants of stable CHO cells
on Protein G sepharose (GE Healthcare, USA), according to the
manufacturer’s protocol. The DNA encoding c-myc peptide was
generated by PCR, sequenced and inserted into the previously
obtained pET22N vector [31]. cDNA encoding the Shiga-like
toxin A-subunit was amplified by PCR from E.coli (E. coli
O157:H7) genomic DNA and cloned into the pET22N. To
obtain chimeric construct of the ETA-c-myc, the sequence
encoding truncated form of ETA (ETA252–608) was amplified
by PCR from the plasmid pIG6-4D5MOCB-ETAH6KDEL [32]
and fused with a DNA fragment encoding c-myc peptide,
generated by PCR. The resulting ETA-c-myc construct was
cloned into the pET-22b(+) vector (Novagen, UK). To obtain
chimeric construct of His-barnase-c-myc, the DNA fragment
encoding c-myc-peptide was reconstituted using a pair of primers,
and a flexible peptide linker (Gly4Ser)3 was added between
barnase module and c-myc-peptide. The DNA fragment encoding
barnase was amplified from the pSD-4D5scFv-barnase vector
[29], subsequently fused with c-myc-(Gly4Ser)3 fragment and
further cloned into the pSD vector. All DNA constructs were
verified by sequencing. To produce the recombinant proteins,
E.coli BL21(DE3) strain was electroporated with pSD-His-barnase-
c-myc (or pET22-c-myc-ETA-His) plasmid and incubated in LB
medium at 25uC. At OD550=0.6 to the bacterial suspension was
added IPTG to the final concentration of 1 mM. Cell culture was
further incubated at 25uC for 12 h. Purification of recombinant
proteins was carried out as described earlier [29]. To produce the
recombinant protein SLT-c-myc, E. coli BL21(DE3) strain was
electroporated with pET22N-SLT-c-myc-His plasmid and further
incubated in LB medium at 37uC. At OD550=0.6 to the bacterial
suspension was added IPTG to the final concentration of 1 mM.
Cell culture was further incubated at 37uC for 6 h, SLT-c-myc
protein was expressed in insoluble inclusion bodies. Cells were
lysed by sonication and inclusion bodies were washed 3 times by
buffer containing 50 mM Tris, 100 mM NaCl, 5 mM EDTA, and
0.5% Triton-X100, pH 8.0. Purified inclusion bodies were
resuspended in 8 M urea (,5 ml per liter of culture), protein
solution was loaded on IMAC column (GE Healthcare, USA) in
PBS - 8 M urea buffer with subsequent refolding on column using
linear gradient of PBS buffer. All prepared proteins were
additionally purified on the Superdex 75 column (GE Healthcare,
USA). SDS-PAGE was performed in 12% polyacrylamide gel
according to the standard protocol. Western blot hybridization
analysis was carried out using Hybond-C transfer membrane
(Amersham Bioscience, UK) according to the manufacturer’s
recommendations, using goat anti-c-myc and anti-mouse HRP-
conjugated Abs (Sigma, USA). Mouse anti-Fc HRP-conjugated
antibody (Sigma, USA) was used in the case of Fc containing
molecules. The immunoblots were visualized using ECL Plus
Western Blotting Detection System (Amersham, UK) and Bio-Rad
VersaDoc 4000 MP imager. Trx-c-myc preparation was describe
previously [9].
In vitro translation in Krebs-2 cells S30 extract
S30 extracts from mice Krebs-2 ascites cells were prepared as
described earlier [33]. Translation experiments were performed in
a total volume of 10 ml containing 3.5 ml of the S30 extract, 1x
B Cell Killing Agents
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0.5 mM spermidine–HCl, 0.6 mM Mg(CH3COO)2, 8 mM crea-
tine phosphate, 1 mM ATP, 0.2 mM GTP, 120 mM CH3COOK
and 25 mM of each amino acid), 2 units of RiboLock Ribonuclease
Inhibitor (Fermentas, Latvia), and 2 ml of PBS buffer containing
various concentrations of barnase, barnase-c-myc, RNAse A,
SLT-c-myc, ETA-c-myc or Trx-c-myc. After 5 min of preincu-
bation at 30uC, 0.25 pmol of m
7G-capped mRNA encoding firefly
luciferase (Fluc) was added [34]. The translation mixtures were
incubated at 30uC for additional 45 min, and the luciferase
activity was measured using the Dual Luciferase Assay kit
(Promega, USA).
RNAse activity test
Fifty ng of barnase-c-myc, barnase and pancreatic RNAse A
were added to 6 mg of total yeast RNA in 10 ml of PBS buffer.
After 1 hour incubation at 37uC, the reaction was stopped by
incubation at 65uC for additional 30 min with subsequent
incubation on ice. Prepared samples were loaded on 1% agarose
gel and visualized by ethidium bromide (0.5 mg/ml).
Binding of C1q complement system component to Fc
and Fc-c-myc molecules
96 well plates were coated overnight at 4uCb ym o n o c l o n a l
human IgGc1, Fc domain of monoclonal human IgGc1
purified after papain hydrolysis, Fc-linker and Fc-linker-c-myc
molecules (all proteins in concentration of 10 mg/ml in
carbonate buffer pH 9.5). Bovine serum albumin was used as
a negative control. C1q component (prepared as described in
[35]) in different concentrations was added to prewashed wells
in veronal buffer pH 7.4 (VBS++). After 1 hour of incubation
wells were washed and treated with rabbit HRP-conjugated
anti-C1q Abs. Finally, OD450 was measured after incubation
with TMB and termination of the reaction by 15% phospho-
rous acid.
Incubation of C-MYC and control hybridomas with
recombinant ITs
Control and C-MYC hybridomas were resuspended and
counted in Goryaev chamber. Cells (10
6 cells/ml) were added
to 24-well plate (Nunc) in 0.5 ml of culture medium. ITs at
different concentrations were added to prepared cells. One
percent of human serum was added to the cells in the case of Fc-
c-myc and Fc. After 72 hours of incubation at 37uCi nt h e
presence of 5% CO2, the number of live cells in each well was
measured using MultiTox-Fluor Multiplex Cytotoxicity Assay
(Promega, USA).
Obtaining of BSA-FITC-c-myc molecule
BSA-FITC molecule was prepared according to the manufac-
turer’s instructions for FITC conjugation (Sigma, USA). The
3 ml of BSA-FITC molecule (1.5 mg/ml) in sodium phosphate
buffer pH 7.4 was incubated for 40 min at 20uCw i t h1 0 0mlo f
10 mg/ml MBS (3-Maleimidobenzoic acid N-hydroxysuccini-
mide ester, Sigma, USA) resuspensed in DMSO. Further sample
was desalted on HiTrap Desalt (GE Healthcare, USA) column to
sodium phosphate buffer pH 6.0. Eluted BSA-FITC-MBS
molecule was added to 500 ml of 10 mg/ml solution of c-myc
peptide with N-terminal cystein (CEQKLISEEDL, synthesized
by solid-state methodology in IBCh RAS). After 3 hours
incubation at 20uC sample was dialyzed against PBS. To check
the ability of obtained BSA-FITC-c-myc molecule to bind anti-c-
myc monoclonal Ab (mAb), 50 mg of conjugate were incubated
with 100 mg of anti-c-myc mAb for 1 h at 37uC. After incubation
sample was loaded on Superdex 200 column (GE Healthcare,
USA). Control injections of non-mixed BSA-FITC-c-myc and
anti-c-myc mAb were performed. Fractions from GFC were
subjected on PAGE and visualized by coomassie staining and
measurement of FITC fluorescence emission.
Immunization of BALB/c mice with KLH-c-myc molecule
The 600 ml of KLH molecule (6 mg/ml) (Fluka) in sodium
phosphate buffer pH 7.4 were incubated for 40 minutes at 20uC
with 50 ml of 10 mg/ml MBS resuspensed in DMSO (Sigma,
USA). Further sample was desalted on HiTrap Desalt (GE
Healthcare, USA) column to sodium phosphate buffer pH 6.0.
Eluted conjugate was incubated with 300 ml of 10 mg/ml solution
of c-myc peptide with N-terminal cystein. After 3 hours incubation
at 20uC sample was dialyzed against PBS. BALB/c mice were
immunized s.c. by 75 mg of KLH-c-myc in complete Freund’s
adjuvant. After 21 days, mice were boosted by i.p. injection of
75 mg KLH-c-myc in PBS.
Incubation of isolated splenocytes with recombinant ITs
Spleens of immunized or intact BALB/c mice were isolated on
24 day after first immunization. Isolated splenocytes were
resuspended and further counted in Goryaev chamber. Cells
(3610
6 cells/ml) were added to 24-well plate (Nunc) in 1 ml of
culture medium. ITs were added to prepared cells in the following
concentrations: barnase and barnase-c-myc (0.55 mM), Fc-linker
and Fc-linker-c-myc molecules (0.1 mM). One percent of human
serum was added to the cells in the case of Fc-c-myc and Fc
analysis. Trx-c-myc (4.5 mM) molecule and 1% human serum
were used as a negative control. Samples of splenocytes were
analyzed in terms of anti-c-myc Abs production and percentage of
c-myc-specific B cells every 24 hours.
Analysis of antibody production by isolated splenocytes.
>Samples of cell supernatants were analyzed by ELISA on 24,
48 and 72 hours after administration of ITs to splenocytes. 96 well
plates were coated by goat anti-whole anti-mouse Ab (Sigma,
USA) or by Trx-c-myc recombinant molecule (0.25 mg/well of
protein in carbonate buffer pH 9.5) and incubated overnight at
4uC. Cell supernatants in different dilutions were added to
prewashed wells and incubated for 1 hour at 37uC. Further wells
were washed and incubated with goat anti-mouse Fc HRP-
conjugated Ab (Sigma, USA) for 1 hour at 37uC. Finally, OD450
was measured after incubation with TMB and termination of the
reaction by 15% phosphorous acid.
Flow cytometry
One million of splenocytes were centrifuged for 10 min at
400 g. Precipitated cells were washed by PBS twice. BFC solution
and anti-B220-APC Ab (eBioscience, USA) in PBS-1%BSA were
added to cells and further incubated for 40 minutes at 4uC.
Stained cells were centrifuged for 10 min at 400 g, resuspended
in FACS buffer (0.1% BSA, 0.02% Azide, 50 ug/ml propidium
iodide in PBS) and analyzed on flow cytometer FACSdiva
(Becton Dickinson, USA).
Results
Construction and purification of recombinant IT
We designed and obtained a set of IT of various cytotoxicity
based on barnase (Figure 1A 1,2), Pseudomonas toxin (Figure 1A 3),
Shiga-like toxin (Figure 1A 4) and human Fc domain (Figure 1A
5,6). Recombinant molecules (2, 3, 4, 6) were fused with c-myc
B Cell Killing Agents
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c-myc epitope (1, 5). All recombinant molecules barnase, barnase-c-
myc, ETA-c-myc, SLT-c-myc contained 6xHis tag. Proteins were
purified usingaffinitychromatographyand additionallysubjected to
GFC on Superdex75/200 columns depending on the protein size.
Purity of the obtained IT was tested by denaturating PAGE
(Figure 1B) and was more than 95%. Purified IT 2, 3, 4 and 6 were
recognized by mAb towards c-myc epitope produced by selected
hybridoma (Figure 1C), while control molecules 1 and 5 showed no
hybridization with these immunoglobulins.
Figure 1. Construction and purification of recombinant IT. (A) Schematic representation of the designed ITs, fused with c-myc epitope
sequence, based on barnase (1 and 2), catalytic (III) and translocation (II) domains of Pseudomonas toxin ETA (3), catalytic (A1) and binding (A2)
domains of Shiga-like toxin E.coli (4) and Fc domain of human antibody IgGc1 (5 and 6). (B) The purity of prepared recombinant molecules was
confirmed by 12% SDS-PAGE. (C) The presence of the c-myc epitope was shown by hybridization of recombinant ITs with anti-c-myc mAbs, produced
by selected hybridoma.
doi:10.1371/journal.pone.0020991.g001
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vitro
To estimate the cytotoxic potential of the obtained IT, we
analyzed their functional activity and specificity in vitro. In the case
of barnase and barnase-c-myc we tested RNAse activity by
incubating these proteins with yeast RNA in the presence and
absence of pancreatic RNAse inhibitor to detect possible
contamination of samples with co-purified prokaryotic RNAses
(Figure 2A). Quantitative analysis of RNA hydrolysis in the
absence of RNAse inhibitor performed by TotalLab software
showed that barnase hydrolyzed yeast RNA with the same rate
when compared with RNAse A, while activity of barnase-c-myc
Figure 2. Functional in vitro activity of obtained IT. (A) Representative hydrolysis of yeast RNA by recombinant barnase, barnase-c-myc and
RNAse A in the absence or presence of RNAse inhibitor. (B) Quantitative analysis demonstrates that presence of pancreatic inhibitor of RNAse A does
not affect the activity of barnase and barnase-c-myc. (C) Suppression of luciferase RNA translation in S30 ascites cell extract by barnase and barnase-c-
myc in the presence or absence of barstar. (D) Barnase and barnase-c-myc are still inhibit luciferase RNA translation in concentrations of three orders
of magnitude less than those for RNAse A. (E) Binding of the C1q component of the complement system to the Fc and Fc-c-myc molecules. Full-size
Abs and their Fc fragments were used as a positive control. Recombinant Fc and Fc-c-myc molecules demonstrate the same affinity compared with
native immunoglobulins. (F) Suppression of luciferase RNA translation in S30 ascites cell extract by Pseudomonas and SLT toxins. Activity of the RIPs
was determined by decreasing of the level of luciferase mRNA translation in mouse Krebs-2 ascites cells S30 extracts depending on the IT
concentration. Total inhibition of protein synthesis was detected at the ETA-c-myc concentration of 75 nM which was five times lower than for the
SLT-c-myc molecule (320 nM). Bars in all experiments represent standard deviation (n=3).
doi:10.1371/journal.pone.0020991.g002
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We found that the pancreatic RNAse inhibitor did not influence
on the activity of barnase and barnase-c-myc, suggesting that
observed RNAse activity completely belonged to barnase and
barnase-c-myc molecules. Barnase activity is not inhibited by
intracellular RNAse inhibitors [36] and is affected only by a
specific inhibitor – barstar . To clarify this, we performed in vitro
translation experiments in S30 cytoplasmic extract of Krebs-2
ascites cells (Figure 2C,D). The extract was pre-incubated with
increasing amounts of barnase, barnase-c-myc and RNAse A, and
then tested for translation of the luciferase mRNA. We showed
that barnase and barnase-c-myc were still active in concentrations
of three orders of magnitude less than those for RNAse A
(Figure 2D). Taking into the account that RNAse A is even more
Figure 3. Functional activity and specificity of the obtained immunotoxins tested ex vivo. ITs’ activity was determined by the ex vivo
elimination of the targeted C-MYC (solid line) and irrelevant (dotted line) hybridoma cell lines depending on the IT’ concentration. IT containing c-
myc sequence selectively killed targeted hybridoma, keeping the irrelevant cells alive. Barnase-c-myc and Fc-c-myc showed rather high cytotoxicity
and specificity. ETA-c-myc was highly cytotoxic for both cell lines. SLT-c-myc molecule showed intermediate level of the cytotoxicity and specificity.
Bars represent standard deviation (n=3).
doi:10.1371/journal.pone.0020991.g003
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suggests that barnase-mediated RNA hydrolysis is substantially
non-affected by intracellular RNA inhibitors.
C1q-binding activity of the Fc and Fc-c-myc molecules was
determined by ELISA (Figure 2E). Briefly, immobilized Fc and Fc-
c-myc molecules were incubated with C1q component of the
complement system with further hybridization with anti-C1q Abs.
Native IgGc1 Abs and Fc domains of these Abs were used as a
positive control. We showed that recombinant Fc and Fc-c-myc
molecules interacted with C1q component of the complement
system with a similar affinity as compared with native IgGc1 Abs.
ETA and SLT toxins affect components of eukaryotic
translational machinery. To test their activities, we used in vitro
translation system based on S30 cytoplasmic extract of Krebs-2
ascites cells. The extract was pre-incubated with increasing
amounts of ETA-c-myc and SLT-c-myc and then assayed for
translation of the luciferase mRNA. Recombinant thioredoxin
fused with c-myc epitope (Trx-c-myc) purified in the same
conditions was used as negative control. Figure 2F indicates the
decrease in translation efficiency in the presence of tested proteins,
with complete inhibition of protein synthesis at the ETA-c-myc
concentration of 75 nM, which was five times lower than that for
the SLT-c-myc molecule (320 nM). Trx-c-myc didn’t have any
detectable effect on eukaryotic translational machinery being used
in concentrations up to 1800 nM. These data indicate that both
ETA-c-myc and SLT-c-myc ITs possess properties of highly
effective inhibitors of the protein synthesis, at least in vitro.
Functional activity and specificity of the obtained ITs ex
vivo
To determine activity of the obtained ITs ex vivo, purified
recombinant proteins were incubated with C-MYC hybridoma
cell line; besides, we used 1B4F4 hybridoma producing irrelevant
Abs as a control. Incubation of the ITs with cells was performed in
24-well plates for 72 h. ITs were added at concentrations ranging
from 0.1 to 2000 nM in order to obtain correct calculations of the
IC50 values. The number of alive cells was measured after 72-h
incubation. Obtained data were used for plotting the curves
showing the dependence of the alive cells amount as a function of
ITs concentration (Figure 3). Recombinant molecules that did not
contain c-myc sequence were used as a negative control. In the
case of Fc-c-myc and Fc molecules, 1% human serum was used as
a source of components of the complement system for effective
elimination of the targeted cells via CDC mechanism.
We detected high functional activity and specificity of the
obtained recombinant molecules. Based on the experimental data
we calculated LD50 of the recombinant toxins towards C-MYC
hybridoma cell line (Table. 1). Fc and barnase molecules, which
did not contain c-myc sequence, served as a negative control in an
addition to the control cell line. It is clearly seen that selective
elimination of the C-MYC hybridoma cell line took place only in
case of application of the IT with c-myc sequence. ETA-c-myc
molecule showed high cytotoxic potential but unexpectedly for
both cell lines. IT based on SLT showed medium values of the
cytotoxicity and specificity as compared to the other ITs. The most
promising results were obtained for the IT based on the barnase
and Fc molecules, which showed the best cytotoxicity/specificity
ratio (Table. 1).
To test barnase- and Fc-based IT on native B cells, BALB/c
mice were immunized with KLH-c-myc to raise B cells pro-
ducing anti-c-myc Abs. We obtained BSA-FITC-c-myc conjugate
(Figure 4A) to uniquely determine c-myc-specific B cells among
total B cells pool. This double labeled protein was tested in terms
of anti-c-myc mAb binding by migration of peak of anti-c-myc
mAb complexed with BSA-FITC-c-myc conjugate (Figure 4B).
Flow cytometry analysis revealed that splenocytes, isolated from
mice immunized with KLH-c-myc, contained 11.2% of B cells
carrying anti-c-myc BCR (Figure 4C, right panels). Splenocytes
from immunized mice were treated by barnase- and Fc-based IT
in optimal concentrations in order to test their cytotoxicity and
specificity. In case of barnase-c-myc we succeeded to show twice
decreasing of the c-myc-specific B cells, while other B cells were
alive (Figure 4C, left panels). Administration of Fc and Fc-c-myc
molecules resulted in unspecific staining of cells during the flow
cytometry analysis. In order to analyze their effect, we performed
comparable analysis of total and anti-c-myc Abs titer, produced by
splenocytes treated by Fc, Fc-c-myc and Trx-c-myc. We detected
5-times decreasing of concentration of anti-c-myc Ab in
splenocytes samples incubated with Fc-c-myc molecule, compared
to control samples (Figure 4D). Importantly, that we didn’t observe
any significant changes in concentration of total IgG suggesting
high selectivity of Fc-c-myc molecule, specifically decreasing
production of anti-c-myc Ab by B cells.
Discussion
Autoreactive B cells are one of the key players in many
autoimmune pathologies. These aggressive pathogenic cells cause
severe tissue damage and malfunction through several pathways.
Antibody-mediated autoimmune diseases may be ameliorated
by immunosuppressive drugs, corticosteroids or plasmapheresis,
which all act only transiently or may be reason of general im-
munodeficiency. Elimination of pathogenic B cells by different ITs
such as MOG-Fc, MOG-ETA and MBP-ETA was reported
previously [39,40,41]. However, there is still no effective therapy
based on the depletion of disease-associated B cells in autoimmune
Table 1. Immunotoxin LD50 determined on model C-MYC and control 1B4F4 cells.
Immunotoxin c-myc epitope LD50 C-MYC cells, nM LD50 1B4F4 cells, nM Specificity**
Pseudomonas toxin (ETA) + 5?10
1 10
3 20
Shiga-like toxin (SLT) + 4.4?10
2 10
5*2 3 0 *
Barnase + 1.1?10
1 10
5*9 0 0 *
2 10
4*1 0
5*-
FcIgGc1 (Fc) + 2.0 10
4* 5000*
2 10
4*1 0
5*-
*More than this value
**LD50(1B4F4)/LD50(C-MYC)
doi:10.1371/journal.pone.0020991.t001
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PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20991Figure 4. Barnase-c-myc and Fc-c-myc specifically deplete anti-c-myc B cells and decrease production of anti-c-myc Ab in culture of
splenocytes, isolated from mice immunized by KLH-c-myc. (A) Procedure of obtaining of BSA-c-myc conjugate labeled by FITC for flow
cytometry detection of targeted anti-c-myc B cells. (i) Conjugation of BSA with FITC using coupling of isothiocyanate with primary amino groups.
(ii) Reaction of free primary amino groups of BSA-FITC with MBS. (iii) Coupling of second functional group of MBS with SH group of N-terminal
cysteine, flanking c-myc peptide. (iv) Final bifunctional reagent BSA-FITC-c-myc, which is capable to react with BCR on the surface of B cells due to the
attached c-myc peptide and carrying fluorescein group for detection. (B) Binding of anti-c-myc mAb to BSA-FITC-c-myc in solution. Superdex 200 gel-
filtration profile of BSA-FITC-c-myc alone (dashed line) and preincubated with anti-c-myc mAb (solid line). Anti-c-myc mAb are shown by thin solid
line. Fractions from gel-filtration chromatography of BSA-FITC-c-myc preincubated with anti-c-myc mAb were subjected on PAGE and visualized by
coomassie staining and measurement of FITC fluorescence emission (bottom panel). (C) Representative flow cytometry analysis of native splenocytes,
isolated from non-immunized and immunized by KLH-c-myc mice, using BSA-FITC-c-myc and anti-B220 APC-labeled antibody (right panels).
Approximately 11% of all B cells carry BCR specific for c-myc peptide (B220
high BSA-FITC-c-myc
high, Q3 quadrant). Representative flow cytometry
analysis of splenocytes, isolated from mice immunized by KLH-c-myc, treated by barnase-c-myc, barnase and Trx-c-myc (left panels from top to
bottom). (D) Analysis of total antibody titer (open figures) and anti-c-myc Abs (filled figures) in samples of splenocytes, isolated from KLH-c-myc
immunized mice, treated by Trx-c-myc (circles), Fc (triangles) and Fc-c-myc (squares) molecules. Bars represent standard deviation (n=3).
doi:10.1371/journal.pone.0020991.g004
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of ITs’ set, based on different molecules and mechanisms of action.
We have designed a panel of ITs based on (i) barnase –
ribonuclease from Bacillus amyloliquefaciens, (ii) catalytic and
translocation domains of Pseudomonas toxin, (iii) catalytic domain
of Shiga-like toxin E.coli, and (iv) Fc fragment of IgGc1 antibody
fused with targeting c-myc sequence. In general, these molecules
consist of two parts: an effector domain (toxin, antibody fragment,
RNAse) and a delivery domain (part or full length autoantigen)
(Figure 5).
The targeting motif of ITs may selectively interact with
pathogenic B cells via their BCR and cause a cell death due to
the attached or internalized toxin. Barnase and RIP inhibit protein
synthesis via hydrolysis of cellular RNA [36,42] and knocking out
of components of eukaryotic translational machinery respectively
[43,44]. A-subunit of Shiga-like toxin consists from two parts:
cytotoxic part A1 and binding part A2 (Figure 1A). During
intracellular toxin transport the furin site between A1 and A2 is
cleaved by furin resulting in the separated carboxy-terminal A2
fragment and cytotoxic A1 fragment (27 kDa), the last one
subsequently escapes from the early endosome [45]. In our study
all artificial elements, including linker, c-myc and 6xHis tags are
fused with A2 fragment. Thus, after endocytosis and furin-
depended release of fully natural fragment A1, it will function
independently according preassigned cell-killing program. Seem-
ingly, nucleotide sequence of designed ETA-c-myc molecule
includes translocation domain II of Pseudomonas toxin, fused with
c-myc sequence (Figure 1A), and released in endosome natural
cytoxic domain III, which further independently delivered to the
cytosole [44]. Thus, chimerical bacterial RIPs described in this
study have natural ability to migrate from endosome to the
cytosole and kill targeted cell. Barnase hasn’t such natural
properties. However, it was reported previously, that barnase
was released from endosomes to cytosole [36]. We showed that, in
contrast with activity of RNAse A, inhibitors existing in eukaryotic
cell extracts did not affect barnase-mediated RNA degradation.
Our data are in accordance with previously findings [36], thus, the
designed ITs based on Barnase should not be affected by
eukaryotic RNAse inhibitors after their internalization. In the
case of Fc-domain-containing molecules, depletion of pathogenic
B cells occurs via the ADCC (antibody dependent cellular
cytotoxicity), CDC (complement dependent cytotoxicity) mecha-
nisms and probably by recently discovered ozone formation [46].
We showed the IT functional activity, e.g. blocking of RNA
translation and subsequently ribosomal protein synthesis by ETA
and SLT molecules, binding of recombinant Fc fragment to C1q
component of the complement system, and finally, the ribonucle-
ase activity of barnase. These experiments suggest that all ITs may
potentially kill cells after simple binding on the surface or
subsequent internalization, if required. The designed ITs were
recognized by mAb produced by targeted hybridoma as shown by
the Western-blotting analysis. Thus, they may bind specifically to
respective BCR on the cell surface and do not interact with
irrelevant cells. Further we compared their legibility and toxic
properties to estimate which of these three approaches would be
the best choice for specific B-cells depletion. With this purpose we
calculated the LD50 of the recombinant toxins for C-MYC and
control hybridoma cell lines. We have shown that selective
elimination of the C-MYC hybridoma cells took place only in case
of application of the IT with c-myc sequence, while Fc and
barnase molecules without c-myc sequence were inactive. ETA-c-
myc molecule showed high cytotoxic effect for both target and
control cell lines. IT based on SLT showed intermediate
cytotoxicity and specificity as compared with other immunotoxins.
Importantly, that ex vivo data of LD50 were correlated with IC50
values, obtained from in vivo experiments, suggesting that cytotoxic
domains of RIPs internalize into the cytosole of targeted cells and
this process is occurred with same efficiency for both SLT and
ETA. The most promising results were obtained for the IT based
on the barnase and Fc molecules, which showed the best
cytotoxicity/specificity ratio (Table. 1), approximately 900 and
5000 units respectively. According to flow cytometry data and IgG
Figure 5. The mechanism of action of designed ITs. Barnase, Shiga-like toxin (SLT) and Pseudomonas toxin (ETA) are recognized by BCR due to
the attached epitope with subsequent endosomal internalization followed by inhibition of protein synthesis via hydrolysis of cellular RNA, N-
glycosylation of 28S rRNA or ADP-ribosylation of EF-2 respectively. In the case of Fc domain, targeted cell death occurs via antibody dependent
cellular cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC).
doi:10.1371/journal.pone.0020991.g005
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PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e20991antibody titer we showed that these ITs were able to specifically
deplete anti-c-myc B cells and decrease production of ant-c-myc
Ab in culture of splenocytes, isolated from mice immunized by
KLH-c-myc.
In summary, we present that SLT and ETA molecules within
their high toxicity also revealed increased unspecific cells
depletion, which is in accordance with previously published results
concerning massive side effects of these ITs. We also report that
barnase and Fc domain are the most actual molecules to design
killers of pathogenic B cells, as they exhibited the least side toxicity
in the reported ITs’ set studied. The Fc molecule has additional
benefit properties due to its high stability in the blood stream and
minimal potential immune response. The presented approach and
selected agents can be efficiently used for design of various
medications for the directed treatments of autoimmune diseases
via selective depletion of the aggressive pathogenic B cells.
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